The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 4012 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 March 2024 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 20 October 2023 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-July 2024 when we will write to you about how you can get involved. |
| 12 April 2023 | Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies have been revised. It is anticipated that the appraisal will begin in late-October 2023 when we will write to you about how you can get involved. |
| 25 October 2022 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early June 2023. |
For further information on our processes and methods, please see our CHTE processes and methods manual